Financial Data
BDTX Financial Data
Revenue · Earnings · Margins · Balance Sheet · Cash Flow
BDTX
Financial DataFinancial Data Overview
Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.
Quarterly Financial Statements
Updated Sep 12, 2026.
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $70M | $0 | $0 |
| Gross Profit | $0 | -$27K | $0 | $0 | -$86K | $70M | $0 | $0 |
| Operating Income | -$12.06M | -$11.26M | -$17.61M | -$10.98M | -$13.42M | $54.53M | -$18.28M | -$18.13M |
| Net Income | -$9.91M | -$9.04M | -$15.12M | -$8.5M | -$10.56M | $56.54M | -$15.99M | -$15.56M |
| EPS | -$0.17 | -$0.16 | -$0.26 | -$0.15 | -$0.19 | $1 | -$0.28 | -$0.28 |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.14M | -$10.23M | -$6.79M | -$7.85M | -$9.16M | $53.41M | -$15.06M | -$11.32M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7.14M | -$10.23M | -$6.79M | -$7.85M | -$9.16M | $53.41M | -$15.06M | -$11.32M |
| Net Cash Provided By Operating Activities | -$7.14M | -$10.23M | -$6.79M | -$7.85M | -$9.16M | $53.41M | -$15.06M | -$11.32M |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $125.03M | $132.92M | $143.01M | $157.73M | $166.39M | $176.25M | $122.64M | $137.9M |
| Total Debt | $16.97M | $17.88M | $18.78M | $19.67M | $20.75M | $21.59M | $22.19M | $23M |
| Cash And Cash Equivalents | — | — | — | — | — | — | — | — |
| Total Liabilities | $28.94M | $28.62M | $30.8M | $31.58M | $33.78M | $34.73M | $39.36M | $40.47M |
| Total Stockholders Equity | $96.09M | $104.3M | $112.21M | $126.15M | $132.61M | $141.52M | $83.29M | $97.43M |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio | -2.72 | -3.33 | -2.34 | -6.32 | -3.26 | 0.39 | -1.91 | -3.88 |
| P/B ratio | 1.1 | 1.17 | 1.24 | 1.7 | 1.06 | 0.62 | 1.45 | 2.52 |
| P/S ratio | 0 | 0 | 0 | 0 | 0 | 1.25 | 0 | 0 |
| Debt To Equity | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 | 0.15 | 0.27 | 0.24 |
| Free Cash Flow Yield | -6.73% | -8.39% | -4.89% | -3.66% | -6.50% | 60.81% | -12.43% | -4.61% |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio | -2.72 | -3.33 | -2.34 | -6.32 | -3.26 | 0.39 | -1.91 | -3.88 |
| P/B ratio | 1.1 | 1.17 | 1.24 | 1.7 | 1.06 | 0.62 | 1.45 | 2.52 |
| P/S ratio | 0 | 0 | 0 | 0 | 0 | 1.25 | 0 | 0 |
| Return On Equity | -10.31% | -8.66% | -13.47% | -6.74% | -7.96% | 39.95% | -19.19% | -15.97% |
| Debt To Equity | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 | 0.15 | 0.27 | 0.24 |
Current Stock Metrics
Current fundamental, technical, and risk readings in one place.
| Metric | Value | Unit | As of |
|---|---|---|---|
| Pe | -2.76 | multiple | Sep 11, 2026 |
| Pb | 1.22 | multiple | Sep 11, 2026 |
| Revenue Growth Yoy | 0 | percent | Sep 11, 2026 |
| EPS Growth Yoy | -6.25 | percent | Sep 11, 2026 |
| Gross Margin | 0 | percent | Sep 11, 2026 |
| Operating Margin | 0 | percent | Sep 11, 2026 |
| ROE | -38.8 | percent | Sep 11, 2026 |
| ROIC | -45.91 | percent | Sep 11, 2026 |
| Debt To Equity | 0.18 | ratio | Sep 11, 2026 |
| FCF Yield | -27.39 | percent | Sep 11, 2026 |
| Metric | Value | Unit | As of |
|---|---|---|---|
| Close | 1.98 | price | Sep 11, 2026 |
| Volume | 588,096 | volume | Sep 11, 2026 |
| Rsi14 | 34.46 | index | Sep 11, 2026 |
| MACD | 0.02 | index | Sep 11, 2026 |
| MACD Signal | 0.05 | index | Sep 11, 2026 |
| MACD Histogram | -0.03 | index | Sep 11, 2026 |
| Adx14 | 24.09 | index | Sep 11, 2026 |
| Sma50 | 1.97 | price | Sep 11, 2026 |
| Sma200 | 2.36 | price | Sep 11, 2026 |
| Atr14 | 0.1 | price | Sep 11, 2026 |
| Historical Volatility | 0.51 | percent | Sep 11, 2026 |
| Volume Ma20 | 542,750.45 | volume | Sep 11, 2026 |
| Metric | Value | Unit | As of |
|---|---|---|---|
| Resilience Score | 37 | score_0_100 | Sep 11, 2026 |
| Beta | 3.29 | ratio | Sep 11, 2026 |
| Volatility Annual | 82.62 | percent | Sep 11, 2026 |
| Max Drawdown | -66.94 | percent | Sep 11, 2026 |
| Sharpe Ratio | -0.2 | ratio | Sep 11, 2026 |
| Var95 | -7.2 | percent | Sep 11, 2026 |
Detailed Metrics
Additional measures remain available here while the decision pages stay focused.
No additional fundamental metrics are available.
No additional technical indicators are available.
No additional risk measures are available.
Related Links
BDTX Financial Data FAQ
What is Black Diamond Therapeutics, Inc.'s revenue?
Black Diamond Therapeutics, Inc.'s revenue is one of the core financial data points for BDTX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is Black Diamond Therapeutics, Inc.'s revenue growing?
Revenue growth shows whether Black Diamond Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is BDTX's EPS?
BDTX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is Black Diamond Therapeutics, Inc.'s net income?
Black Diamond Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does Black Diamond Therapeutics, Inc. generate?
Free cash flow shows how much cash Black Diamond Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does Black Diamond Therapeutics, Inc. have?
Cash and debt help frame BDTX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.